Aimmune Therapeutics (AIMT) Tops Q2 EPS by 3c

Aimmune Therapeutics (NASDAQ: AIMT) reported Q2 EPS of ($1.06), $0.03 better than the analyst estimate of ($1.09).

“We are encouraged that an increasing number of allergy practices around the country have re-opened since June. As a result, we have also seen a corresponding inflection in our leading indicator launch metrics. Given this momentum, we have initiated a targeted digital and print marketing campaign to create greater awareness of PALFORZIA among patients and their caregivers in the U.S.,” said Jayson Dallas, M.D., President and Chief Executive Officer of Aimmune Therapeutics. “Our overall business fundamentals and long-term prospects remain strong, and we are confident in the thoughtful manner in which we are navigating this ongoing pandemic.”

For earnings history and earnings-related data on Aimmune Therapeutics (AIMT) click here.

You May Also Be Interested In

• Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
• Intel slides in afterhours trading as Q1 revenue misses, Q2 outlook falls short
• Nomura Holdings (NMR) Reports In-Line Q1 EPS